Aarti Pharmalabs Limited — Others, 12-08-2025: Appointment

The company's Board of Directors has approved the financial results for the quarter, reporting a standalone net profit of ₹51.22 Cr on ₹375.31 Cr revenue, and a consolidated net profit of ₹49.50 Cr on ₹386.19 Cr revenue. Due to Ganesh Polychem Limited becoming a joint venture, consolidated figures are not comparable with previous periods. The Board also approved the appointment of M/s Mehta and Mehta as Secretarial Auditors for five years and the re-appointment of Ms. Rupal Vora as an Independent Director for three years, both subject to shareholder approval. Additionally, the Aarti Pharma Stock Option Scheme will be extended to eligible employees of subsidiary companies.